Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
June 6, 2025MadridIn recruitment
MK-5909-003 Phase 1b/2 clinical trial to evaluate safety and efficacy of raludotatug deruxtecan, with or without other drugs in participants with high-grade serous epithelial ovarian carcinoma, primary peritoneal carcinoma or tubal carcinoma.
The main objective is to evaluate the safety and tolerability of raludotatug deruxtecan (R-DXd) administered in combination with carboplatin in participants with recurrent high-grade ovarian carcinoma. -
June 4, 2025PamplonaIn recruitmentEarly phase
EZH-302 Ensayo clinico para evaluar la eficacia, seguridad, farmacodinamia y farmacocinética de tazemetostat en combinación con lenalidomida más rituximab versus placebo en combinación con lenalidomida más rituximab [SP]
The purpose of this study is to see how safe and effective (useful) the investigational drug tazemetostat is when given with anticancer drugs lenalidomide and rituximab in people with relapsed or refractory follicular lymphoma. -
May 28, 2025Pamplona/MadridIn recruitment
D7080C00001 Trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of AZD0022 in monotherapy and in combination with antineoplastic agents in patients with tumors carrying a KRASG12D mutation (ALAFOSS-01).
The objective of the research trial is to obtain more information about AZD0022 and also to better understand the disease being studied and the associated health problems. -
May 28, 2025Pamplona/MadridIn recruitment
20230005 Randomized, open-label, multicenter clinical trial of xaluritamig vs. cabazitaxel or a second androgen receptor-targeted therapy in subjects with metastatic castration-resistant prostate cancer.
This study is being conducted to learn more about the safety and efficacy of xaluritamig compared to already approved standard treatments in patients with prostate cancer that has spread to other parts of the body (also called metastatic castration-resistant prostate cancer [mCRPC]) who have already been treated with chemotherapy. -
May 27, 2025PamplonaIn recruitmentEarly phase
1456-0001 Study to evaluate different doses of BI 1831169 alone and in combination with ezabenlimab in people with different types of advanced cancer (solid tumors).
The aim of the study is to find out the highest amount of BI 1831169 that can be administered without too many side effects, both alone and in combination with another drug (ezabenlimab), as well as to observe the effect it may have on cancerous tumors and on the body. -
May 26, 2025Pamplona/MadridIn recruitment
CCS1477-02 Phase I/IIa open-label clinical trial to evaluate the safety and efficacy of CCS1477 in monotherapy and in combination in patients with advanced hematologic malignancies.
The goals of this clinical trial are to find out the side effects of CCS1477, find out the maximum tolerated dose of CCS1477, understand how the body processes CCS1477 (called pharmacokinetics [PK]), understand what CCS1477 does to the body, find out if CCS1477 can be given with other cancer drugs, and find out what effect CCS1477 has on cancer proliferation. This information will help decide what dose and how often to give CCS1477 to participants in future clinical trials. -
May 26, 2025Pamplona/MadridIn recruitmentEarly phase
GO45296 Trial of ro7759065 in monotherapy and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.
The purpose of this study is to test RO7759065 at different doses, either given as monotherapy or in combination with atezolizumab, to determine if it is safe and to learn how your body processes the drugs. RO7759065 and atezolizumab are immunotherapeutic anticancer drugs. -
May 22, 2025Pamplona/MadridIn recruitment
GCT1046-06 Phase III, prospective, randomized, unblinded, randomized trial of acasunlimab (GEN1046) in combination with pembrolizumab vs. docetaxel in subjects with PD-L1-positive metastatic non-small cell lung carcinoma
The objective of this study is to analyze the efficacy of acasunlimab in combination with pembrolizumab. -
May 22, 2025PamplonaIn recruitmentEarly phase
90189892AML1001 Phase I study of JNJ-90189892 for relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasms
The aim of this first-in-human study is to help researchers learn more about the potential efficacy and safety of JNJ-90189892 in people with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS, also called myelodysplastic syndrome). -
May 14, 2025Pamplona/MadridIn recruitmentEarly phase
LAVA-1266-001 Estudio defase 1, abierto, para evaluar la seguridad, la tolerabilidad, la farmacocinética, la farmacodinámica, la inmunogenicidad y la actividad antitumoral preliminar del LAVA-1266 [SP]
The purpose of this clinical research study is to determine whether the study drug, LAVA-1266, can help people with relapsed/refractory AML and intermediate-risk, high-risk or extremely high-risk MDS.